Key result
Triple-site pacing CRT is linked to ~72% fewer heart failure events vs dual-site pacing.
Why the study?
Dual-site pacing CRT may not fully eliminate electrical dyssynchrony, and the long-term effects of triple-site CRT guided by temporary pacing remained to be determined.
Does triple-site cardiac resynchronization therapy guided by temporary pacing reduce heart failure events and improve clinical outcomes compared to dual-site therapy in patients with HFrEF and prolonged QRS duration?
Cohort (n=92)
No
Does triple-site cardiac resynchronization therapy guided by temporary pacing reduce heart failure events and improve clinical outcomes compared to dual-site therapy in patients with HFrEF and prolonged QRS duration?
Hazard Ratio: 0.275 (95% CI 0.095–0.8)
p-value: p=0.018
Triple-site cardiac resynchronization therapy, when guided by temporary pacing to optimize electrical synchrony, significantly reduces long-term heart failure events compared to conventional dual-site therapy.
Background: Cardiac resynchronization therapy (CRT) is an effective treatment for chronic heart failure, but dual-site (2V) pacing may not fully eliminate electrical dyssynchrony. Triple-site (3V) pacing, adding an additional left ventricle (LV) pacing site, may enhance CRT outcomes. Objective: This study examines the long-term effects of 2V vs 3V CRT, using temporary pacing to individualize lead placement. Methods: From 2010 to 2016, 92 patients with New York Heart Association (NYHA class II-IV heart failure, left ventricular ejection fraction (LVEF) < 35%, and QRS duration > 120 ms received CRT guided by temporary pacing. Patients underwent invasive pacing studies to measure electrical and hemodynamic improvements between 2V and 3V configurations. Based on QRS narrowing and LV dP/dtmax improvements, 27 patients were assigned to the 3V group and 65 to the 2V group. Clinical outcomes, including the clinical composite score (CCS), NYHA class, QRS duration, heart failure (HF) events, and mortality, were followed up over an average 8.3 years. Results: = .018). Despite shorter battery life in the 3V group, device replacement rates were similar. Conclusion: Temporary pacing-guided 3V CRT provides significant long-term benefits over 2V CRT by reducing HF events. These findings support the necessity of individualized assessment and approach to eliminate electrical dyssynchrony when considering multi-site pacing CRT.
No takes yet. Share an insight, caveat, or question.
Ogano et al. (2025) conducted a cohort in Heart failure with reduced ejection fraction (LVEF < 35%) and wide QRS (> 120 ms) (n=92). Triple-site (3V) cardiac resynchronization therapy vs. Dual-site (2V) cardiac resynchronization therapy was evaluated on Heart failure events (HR 0.275, 95% CI 0.095-0.800, p=0.018). Triple-site pacing cardiac resynchronization therapy significantly reduced the risk of heart failure events compared to dual-site pacing (HR 0.275, 95% CI 0.095-0.800, p=0.018).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: